1. Home
  2. L vs INSM Comparison

L vs INSM Comparison

Compare L & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Loews Corporation

L

Loews Corporation

HOLD

Current Price

$115.79

Market Cap

24.4B

Sector

Finance

ML Signal

HOLD

Logo Insmed Incorporated

INSM

Insmed Incorporated

HOLD

Current Price

$130.21

Market Cap

22.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
L
INSM
Founded
1969
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.4B
22.4B
IPO Year
2000
2000

Fundamental Metrics

Financial Performance
Metric
L
INSM
Price
$115.79
$130.21
Analyst Decision
Strong Buy
Analyst Count
0
24
Target Price
N/A
$201.17
AVG Volume (30 Days)
715.5K
2.6M
Earning Date
05-04-2026
05-07-2026
Dividend Yield
0.22%
N/A
EPS Growth
24.34
N/A
EPS
3.79
N/A
Revenue
$18,454,000,000.00
N/A
Revenue This Year
N/A
$182.31
Revenue Next Year
N/A
$65.19
P/E Ratio
$30.54
N/A
Revenue Growth
5.39
N/A
52 Week Low
$93.25
$90.39
52 Week High
$121.01
$212.75

Technical Indicators

Market Signals
Indicator
L
INSM
Relative Strength Index (RSI) 57.27 74.77
Support Level $102.18 $105.07
Resistance Level $120.06 $166.34
Average True Range (ATR) 2.01 3.25
MACD -0.30 1.12
Stochastic Oscillator 44.94 96.88

Price Performance

Historical Comparison
L
INSM

About L Loews Corporation

Loews Corp is a holding company along with its subsidiary engaged in commercial property and casualty insurance, transportation and storage of natural gas and natural gas liquids, operation of a chain of hotels, and also in the manufacture of rigid plastic packaging solutions. It has four reportable segments comprised of three individual consolidated operating subsidiaries, CNA Financial Corporation, Boardwalk Pipeline Partners, LP and Loews Hotels Holding Corporation; and the Corporate segment.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Share on Social Networks: